Succinylation Antibodies: Unveiling the Pivotal Role of Protein Modification in Disease Pathogenesis—A Literature Analysis

1. Literature Information

• Research Topic: The regulatory role of protein succinylation in tumorigenesis, metabolic disorders, and degenerative diseases
• Core Findings: Succinylation dysregulation drives disease progression by modulating metabolic enzyme activity, mitochondrial function, and transcriptional regulation; targeted inhibition of aberrant succinylation offers therapeutic potential
• Key Tools: Succinylation antibodies (pan-specific and application-optimized) from ANT BIO PTE. LTD.
• Application Scenarios: Tumor metabolism research, degenerative disease mechanism exploration, metabolic enzyme regulation studies, and drug development

2. Research Background

Protein succinylation is a critical post-translational modification (PTM) involving the covalent attachment of a succinyl group to lysine residues—catalyzed enzymatically or non-enzymatically with succinyl-CoA as the donor. This modification is extensively involved in regulating core energy metabolism pathways, including the tricarboxylic acid (TCA) cycle and glucose metabolism, and is essential for maintaining cellular energy homeostasis.

In recent years, accumulating evidence has linked succinylation dysregulation to the pathogenesis of diverse diseases, such as tumors, neurodegenerative disorders, metabolic syndromes, and inflammatory responses. The dynamic balance of succinylation is co-regulated by succinyltransferases and desuccinylases (e.g., SIRT5, the major desuccinylase). However, the specific molecular mechanisms by which succinylation drives disease progression remained unclear, highlighting the need for high-quality detection tools to dissect this modification’s biological functions. Succinylation antibodies from ANT BIO PTE. LTD. emerged as indispensable tools to address this gap.

3. Research

1. Disease-Associated Succinylation Profiling: Identify aberrantly succinylated proteins in disease models (e.g., tumors, degenerative diseases) using succinylation antibodies combined with proteomic analysis.
2. Functional Validation of Target Proteins: Verify the role of key succinylated proteins (e.g., LDHA, AIFM1, p23) in disease progression via gene editing (knockdown, point mutations) and in vitro functional assays.
3. Mechanistic Exploration: Elucidate how succinylation modulates protein function (enzymatic activity, subcellular localization, protein-protein interactions) and downstream signaling pathways.
4. Therapeutic Potential Assessment: Evaluate whether targeting succinylation (e.g., inhibiting aberrant succinylation, activating desuccinylases) alleviates disease phenotypes in preclinical models.
5. Clinical Correlation Analysis: Explore the association between succinylation levels of key proteins and disease prognosis or treatment response in clinical samples.

4. Research Results

4.1 Succinylation Promotes Tumor Metabolism and Therapy Resistance

• In papillary thyroid carcinoma, long non-coding RNA GLTC is overexpressed, correlating with distant metastasis and poor prognosis.
• GLTC binds to lactate dehydrogenase A (LDHA), competitively inhibiting SIRT5-LDHA interaction and promoting LDHA succinylation at K155.
• This modification enhances LDHA enzymatic activity, boosting aerobic glycolysis and tumor cell viability, thereby promoting malignant progression.
• The succinylation-mimetic mutant LDHAK155E restores glycolysis and cell viability in GLTC-knockdown cells.
• GLTC-mediated LDHA succinylation reduces tumor sensitivity to radioactive iodine therapy, identifying the GLTC-LDHA succinylation axis as a potential therapeutic target.

4.2 Desuccinylation Maintains Mitochondrial Homeostasis and Delays Degenerative Diseases

• In intervertebral disc degeneration, mechanical stress reduces SIRT5 expression in rat nucleus pulposus tissue, impairing mitochondrial function and increasing apoptosis.
• Proteomic analysis identifies apoptosis-inducing factor mitochondria-associated 1 (AIFM1) as a key SIRT5 substrate.
• Decreased SIRT5 leads to elevated AIFM1 succinylation, disrupting AIFM1-CHCHD4 interaction, reducing electron transport chain complex subunits, and causing mitochondrial dysfunction.
• SIRT5 knockout mice exhibit more severe intervertebral disc degeneration after lumbar destabilization surgery, while SIRT5 overexpression or methylene blue treatment alleviates mitochondrial damage and disease progression.

4.3 Succinylation Regulates Transcription and Tumorigenesis

• In lung adenocarcinoma, succinate accumulation in tumor cells induces p23 succinylation at K7, K33, and K79 sites.
• Succinylation drives p23 nuclear translocation, where it acts as a transcription factor to activate COX-2 expression, promoting tumor growth.
• Small molecule compound M16, identified via virtual screening, inhibits p23 succinylation, blocks nuclear translocation and COX-2 activation, and significantly suppresses tumor growth.

5. Product Empowerment

ANT BIO PTE. LTD.’s STARTER brand succinylation antibodies played a pivotal role in all critical research stages, delivering exceptional performance:

1. Succinyllysine Rabbit Polyclonal Antibody (STARTER Sub-Brand, Catalog No.: S0B1272):
• Enabled global succinylation profiling via Western blot, providing initial evidence of aberrant succinylation in disease models.
• Supported immunoprecipitation (IP) experiments to enrich succinylated proteins, facilitating proteomic identification of key targets (e.g., LDHA, AIFM1, p23).
• Validated site-specific succinylation in clinical samples and preclinical models, ensuring reliable correlation analysis.
2. Anti-Succinyllysine Agarose Beads (STARTER Sub-Brand, Catalog No.: S0F0010):
• Facilitated efficient enrichment of succinylated proteins from complex biological samples, enhancing the sensitivity of proteomic analysis.
3. Core Product Advantages:
• High modification specificity: Cross-validated with modified/unmodified peptides, showing no cross-reactivity with other acylations (e.g., acetylation, crotonylation).
• Broad-spectrum recognition: Polyclonal nature enables detection of succinylation across diverse protein backgrounds.
• Excellent affinity and batch consistency: Efficiently detects endogenous succinylated proteins, with stable performance supporting long-term research.

 7. Brand Mission

ANT BIO PTE. LTD. is a leading provider of life science reagents, offering a comprehensive portfolio including antibodies, recombinant proteins, kits, and general laboratory reagents. We operate three specialized sub-brands:

• Absin: Focuses on general reagents and kits for broad experimental applications.
• Starter: Specializes in high-quality antibodies, including post-translational modification-specific antibodies like succinylation antibodies.
• UA: Concentrates on recombinant proteins for functional studies and drug development.

Guided by the principle of "Empowering Scientific Discovery Through Precision Reagents," we adhere to strict international quality standards (EU 98/79/EC, ISO9001, ISO13485) and advanced development platforms (e.g., recombinant antibody technology, multi-system protein expression). Our mission is to provide researchers worldwide with reliable, high-performance tools and professional technical support, accelerating breakthroughs in metabolism, oncology, degenerative diseases, and other frontier fields to advance human health.

8. Related Product List

9. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.